BGS vs NUS

BGS has a Piotroski F-Score of 5/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite deeply depressed valuation multiples—Price/Book of 0.75 and Price/Sales of 0.19—the company is unprofitable on a net basis with a -13.61% profit margin and an alarming -40.86% ROE. The dividend yield of 17.76% is unsustainable given a 333.33% payout ratio, and insider selling, weak earnings surprises, and negative revenue growth further undermine confidence. While recent EPS growth appears strong, it stems from a low base after prior losses, and the stock trades below analyst target prices, signaling limited upside.

NUS presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a bearish technical trend of 0/100. While the company is trading at a massive discount to its Graham Number ($34.57) and Intrinsic Value ($22.26), this is offset by a severe revenue contraction of -16.90% YoY. The balance sheet remains healthy with low debt (D/E 0.38) and strong liquidity, but the operational decay suggests the market is pricing in a permanent decline in the business model.